$336m funding to help develop vaccine production in Bangladesh

In:

Social infrastructure, Social projects

Region:

Asia-Pacific

ADB has approved a loan package of $336.5 million to establish domestic vaccine, therapeutics, and diagnostics manufacturing capacity and strengthen...

Exclusive subscriber content…

If you are an Uxolo subscriber, please login to continue reading

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to Uxolo Intelligence contact us

Request Access

Is securitisation the panacea for private capital mobilisation?

Perspective

29 May 2025

Is securitisation the panacea for private capital...

Since 2023, the IFC's securitisation has become a flagship strategy and now the EBRD is committed to realising its first synthetic risk transfer (SRT) by year-end. But in...

Why MDBs are tapping short-term bonds in 2025

Perspective

06 June 2025

Why MDBs are tapping short-term bonds in 2025

If the long end of the bond market were a dinner party, right now you’d hear a lot of awkward coughs and clinking ice as uncertainty grows and term premiums rise. Meanwhile,...

Must See

20 minutes with: Faruq Muhammad, Standard Chartered

Video

06 May 2025

20 minutes with: Faruq Muhammad, Standard Chartered

Uxolo speaks with Faruq Muhammad, Global Head, Development & Agency Finance at Standard Chartered Bank, guiding listeners through candid conversations on the bank’s role in global development finance, highlighting both challenges and opportunities across emerging markets. Faruq raises several thought-provoking topics that reveal how Standard Chartered operates at the intersection of commercial banking and development impact.

Perspective

29 May 2025

Is securitisation the panacea for private capital mobilisation?

Since 2023, the IFC's securitisation has become a flagship strategy and now the EBRD is committed to realising its first synthetic risk transfer (SRT) by year-end. But in reality, actual risk transfer remains the outlier, not the norm. Is this product the magic bullet MDBs need to mobilise private capital?

Perspective

06 June 2025

Why MDBs are tapping short-term bonds in 2025

If the long end of the bond market were a dinner party, right now you’d hear a lot of awkward coughs and clinking ice as uncertainty grows and term premiums rise. Meanwhile, MDBs have pivoted to shorter liabilities with less execution risk and tighter pricing.